BLPH Stock Overview
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$2.48|
|52 Week High||US$9.19|
|52 Week Low||US$2.35|
|1 Month Change||-27.49%|
|3 Month Change||-39.22%|
|1 Year Change||-63.10%|
|3 Year Change||-84.97%|
|5 Year Change||-69.29%|
|Change since IPO||-98.16%|
Recent News & Updates
|BLPH||US Medical Equipment||US Market|
Return vs Industry: BLPH underperformed the US Medical Equipment industry which returned 8.9% over the past year.
Return vs Market: BLPH underperformed the US Market which returned 16.5% over the past year.
|BLPH Average Weekly Movement||7.7%|
|Medical Equipment Industry Average Movement||7.6%|
|Market Average Movement||6.2%|
|10% most volatile stocks in US Market||14.8%|
|10% least volatile stocks in US Market||2.4%|
Stable Share Price: BLPH is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: BLPH's weekly volatility (8%) has been stable over the past year.
About the Company
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its products include INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 2 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; that has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that is in Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension, pulmonary hypertension associated with pulmonary edema from high altitude sickness, and COVID-19 patients.
Bellerophon Therapeutics Fundamentals Summary
|BLPH fundamental statistics|
Is BLPH overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|BLPH income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-2.26|
|Net Profit Margin||0.00%|
How did BLPH perform over the long term?See historical performance and comparison
Is Bellerophon Therapeutics undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: BLPH ($2.48) is trading below our estimate of fair value ($145.32)
Significantly Below Fair Value: BLPH is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: BLPH is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: BLPH is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BLPH's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BLPH is good value based on its PB Ratio (0.9x) compared to the US Medical Equipment industry average (3.7x).
How is Bellerophon Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BLPH is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BLPH is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BLPH is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: BLPH's revenue (66.3% per year) is forecast to grow faster than the US market (9.8% per year).
High Growth Revenue: BLPH's revenue (66.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BLPH's Return on Equity is forecast to be high in 3 years time
How has Bellerophon Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BLPH is currently unprofitable.
Growing Profit Margin: BLPH is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BLPH is unprofitable, but has reduced losses over the past 5 years at a rate of 14.5% per year.
Accelerating Growth: Unable to compare BLPH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BLPH is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (51.2%).
Return on Equity
High ROE: BLPH has a negative Return on Equity (-83.32%), as it is currently unprofitable.
How is Bellerophon Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: BLPH's short term assets ($29.7M) exceed its short term liabilities ($5.1M).
Long Term Liabilities: BLPH's short term assets ($29.7M) exceed its long term liabilities ($397.0K).
Debt to Equity History and Analysis
Debt Level: BLPH is debt free.
Reducing Debt: BLPH has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BLPH has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if BLPH has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Bellerophon Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BLPH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BLPH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BLPH's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BLPH's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BLPH's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Peter Fernandes (66 yo)
Mr. Peter Fernandes, M. Pharm, has been the Chief Regulatory and Safety Officer of Bellerophon Therapeutics, Inc. since May 2015 and serves as its Interim Principal Executive Officer since November 11, 202...
CEO Compensation Analysis
Compensation vs Market: Peter's total compensation ($USD476.35K) is about average for companies of similar size in the US market ($USD567.11K).
Compensation vs Earnings: Peter's compensation has been consistent with company performance over the past year.
Experienced Management: BLPH's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.
Experienced Board: BLPH's board of directors are considered experienced (5.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Bellerophon Therapeutics, Inc.'s employee growth, exchange listings and data sources
- Name: Bellerophon Therapeutics, Inc.
- Ticker: BLPH
- Exchange: NasdaqCM
- Founded: 2009
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$23.576m
- Shares outstanding: 9.51m
- Website: https://www.bellerophon.com
Number of Employees
- Bellerophon Therapeutics, Inc.
- 184 Liberty Corner Road
- Suite 302
- New Jersey
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/12/07 00:34|
|End of Day Share Price||2021/12/06 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.